Pain Management Drugs Market to Reach $1.04 Bn by 2027 | Eli Lilly & Company, Abbott Laboratories, Purdue Pharma L.P., Pfizer, Inc., Mylan NV.

Surge in incidences of chronic diseases, supportive regulatory scenario, and rise in aging population drive the growth of the gulf pain management drugs market. However, availability of alternative therapies, drug exploitation, and patent expiration of prescription drugs hinder the market growth. On the other hand, advancements in drug development create new opportunities in the coming years.

According to the report published by Allied Market Research, the gulf pain management drugs industry generated $851.08 million in 2019, and is expected to reach $1.04 billion by 2027, witnessing a CAGR of 3.2% from 2020 to 2027. The report provides a detailed analysis of changing market dynamics, top segments, value chain, key investment pockets, regional scenario, and competitive landscape.

Download Sample Report at:

https://www.alliedmarketresearch.com/request-sample/10718

Increase in prevalence of chronic diseases, favorable regulatory scenario, and surge in the number of geriatric population drive the growth of the global pain management drugs market. On the other hand, availability of alternative therapies, drug exploitation, and patent expiration of prescribed drugs impede the growth to some extent. However, advancements in drug development and untapped markets in developing economies are expected to create lucrative opportunities for the market players in the industry.

Onkar Sumant, a Manager, Healthcare at Allied Market Research, stated, “The growth of the Gulf pain management drugs market is attributed to increase in R&D investment and outsourcing of pharmaceutical companies due to strong need for better treatment lead to growth in pain management drugs market. Moreover, surge in prevalence of chronic diseases, such as cancer, diabetic neuropathy, and osteoarthritis propels the market growth.”

Covid-19 Scenario

  • Pain management services in many clinics in the gulf countries stopped offering services to ensure safety and avoid cross-contamination. Only cases involving management of chronic pain were served in the clinics and hospitals.
  • Telemedicine services became prominent during the pandemic and physicians and consultants began offering their consultation through video calling and phone calls to ensure safety.
  • During the post-lockdown, clinics are expected to open up for physical visits of patients and the demand is expected to rise steadily.  

Postoperative pain and chronic back pain were among the largest revenue contributors in 2019, owing to increase in number of surgeries in the Gulf countries such as Saudi Arabia, Oman and rise in prevalence of chronic diseases that lead to back pain. Furthermore, the cancer pain segment is expected to grow at the highest rate throughout the forecast period, owing to rise in prevalence of cancer.

Saudi Arabia to maintain its dominant share by 2027

Based on country, Saudi Arabia contributed to the highest share in terms of revenue in 2019, accounting for nearly three-fifths of the gulf pain management drugs market, and will maintain its dominant share by 2027. This is attributed to rise in healthcare expenditure and ease in availability of pain management products. The report also analyzes the segments including the United Arab Emirates, Oman, and the rest of the gulf countries.

Enquiry for Short-term and Long-term Impacts of COVID-19 at: https://www.alliedmarketresearch.com/purchase-enquiry/10718

Leading market players

  • Novartis AG
  • Eli Lilly & Company
  • Abbott Laboratories
  • Purdue Pharma L.P.
  • Pfizer, Inc.
  • Mylan NV.
  • Merck & Co. Inc.
  • Johnson & Johnson
  • Gulf Pharmaceutical Industries (Julphar)
  • Oman pharmaceutical products Co. Llc
  • GlaxoSmithKline Plc.

Avenue Basic Plan | Library Access | 1 Year Subscription |

Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains.

Contact us:

David Correa

5933 NE Win Sivers Drive

#205, Portland, OR 97220

United States

Toll Free: 1-800-792-5285 |UK: +44-845-528-1300 | Hong Kong: +852-301-84916 | India (Pune): +91-20-66346060 | Fax: +1-855-550-5975 Email” help@alliedmarketresearch.com
Follow us on LinkedIn, Facebook, Twitter, Pinterest, YouTube & Instagram

Leave a comment

Your email address will not be published. Required fields are marked *